Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered question first ministerially corrected answering member label previous answer version answering member printed answering member label
tabling member	label

Search

1126321

	registered interest
	date	13/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Gender Dysphoria: Children
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they intend to publish the results of the research project started in 2011 by the NHS Gender Identity Development Service Early pubertal suppression in a carefully selected group of adolescents with gender identity disorder; and if not, whether they will arrange for the data gathered by that study to be made available to other researchers.
	tabling member printed	Lord Lucas
	uin	HL15681
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>The research is an ethically approved study being carried out by the Tavistock and Portman NHS Foundation Trust since 2011, which is the largest provider of services for the alleviation of gender dysphoria in the United Kingdom.</p><p>The study will evaluate early pubertal suppression in a carefully selected group of adolescents with a clinical diagnosis of gender dysphoria. There are 44 young people taking part in the study.</p><p>The Tavistock and Portman NHS Foundation Trust has plans to publish the data <ins class="ministerial">on the blocker and cross-sex hormones, for those who were appropriate for this, as</ins><del class="ministerial">once</del> all of the young people in the study have reached <ins class="ministerial">this</ins><del class="ministerial">the</del> stage<ins class="ministerial">.</ins> <del class="ministerial">when a clinical decision is made about moving from pubertal suppressants to cross-sex hormones, which the Trust expects to occur in the next 12 months.</del></p> answering member printed Baroness Blackwood of North Oxford question first answered 22/05/2019 14:51:30 question first ministerially corrected 31/07/2019 15:30:59 answering member 4019 label Biography information for Baroness Blackwood of North Oxford previous answer version 119577 answering member printed Baroness Blackwood of North Oxford answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1879 label Biography information for Lord Lucas

1126557

	registered interest
	date	14/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Department of Health and Social Care: Sick Leave
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of officials in his Department took sick leave for reasons relating to stress in the last 12 months; what proportion that leave was of total sick leave taken in his Department; and what the cost was to his Department of officials taking sick leave over that period.
	tabling member constituency	Carshalton and Wallington
	tabling member printed	Tom Brake
	uin	254066
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>The number of employees in the Department from 1 April 2018 to 31 March 2019 who were absent due to mental health reasons, including stress was 46, this represented 3% of the total workforce. The proportion of sickness absence related to mental health reasons, including stress, was 22% of the overall sickness absence for the Department for the same time period.</p><p> </p><p>The estimated cost to the Department from 1 April 2018 to 31 March 2019 for employees taking sickness absence, is estimated at £936,927.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 22/05/2019 10:28:23 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	151 label Biography information for Tom Brake

1127283

	registered interest
	date	17/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to encourage fairer pricing by pharmaceutical companies for drugs supplied to the NHS.
	tabling member constituency	Coventry South
	tabling member printed	Mr Jim Cunningham
	uin	255651
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>The 2019 Voluntary Scheme for Branded Medicines Pricing and Access, and the statutory scheme for branded medicines pricing, work together to control the cost of branded medicines to the National Health Service and ensure it stays within affordable limits.</p><p> </p><p>The 2019 Voluntary Scheme began on 1 January 2019 and will run for five years until the end of 2023. The Voluntary Scheme aims to provide stability and predictability for all parties in terms of the United Kingdom’s branded medicines expenditure and the medicines pricing and access environment for the period 2019 to 2023. It also aims to achieve a balance between patient access, affordability and supporting the development of innovative new medicines, including support for small companies.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/05/2019 14:30:06 answering member 4455 label Biography information for Seema Kennedy
	tabling member	308 label Biography information for Mr Jim Cunningham

1127317

	registered interest
	date	17/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Bowel Cancer: Young People
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to reduce the number of young people developing bowel cancer.
	tabling member constituency	Coventry South
	tabling member printed	Mr Jim Cunningham
	uin	255652
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>Obesity and poor diet are risk factors for bowel cancer in young people.</p><p>The second chapter of the world-leading childhood obesity plan was published in June 2018. This builds on the real progress made since the publication of chapter one in 2016, particularly in reformulation of the products our children eat and drink most. In chapter two we have set a bold ambition to halve childhood obesity by 2030 and significantly reduce the gap in obesity between children from the most and least deprived areas by 2030.</p><p>Many of the measures in both chapters of the plan will have an impact on tackling obesity across all age groups. These include the soft drinks industry levy, sugar reduction and wider calorie reformulation programme, restricting promotions and calorie labelling in restaurants which will improve our eating habits and reduce the amount of sugar we consume.</p><p>‘Childhood obesity: a plan for action, chapter 2’ is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/childhood-obesity-a-plan-for-action-chapter-2" target="_blank">www.gov.uk/government/publications/childhood-obesity-a-plan-for-action-chapter-2</a></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/05/2019 14:24:08 answering member 4455 label Biography information for Seema Kennedy
	tabling member	308 label Biography information for Mr Jim Cunningham

1127168

	registered interest
	date	16/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Urinary Tract Infections
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to reduce unplanned hospital admissions resulting from urinary tract infections.
	tabling member constituency	Hornsey and Wood Green
	tabling member printed	Catherine West
	uin	255355
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>In England, it is the responsibility of National Health Service commissioners to make decisions on individual treatments for urinary tract infections on the basis of the available evidence, taking into account guidance from the National Institute for Health and Care Excellence (NICE) where available. NICE guidance is always evidence based, adhering to the latest clinical thinking and research to determine the best treatment for patients.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/05/2019 14:26:35 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4523 label Biography information for Catherine West

1127170

	registered interest
	date	16/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Urinary Tract Infections
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to improve the (a) reporting and (b) tracking of urinary tract infections in the NHS; and if he will make a statement.
	tabling member constituency	Hornsey and Wood Green
	tabling member printed	Catherine West
	uin	255357
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>NHS Digital’s Hospital Episodes Statistics publishes data on finished consultant episodes with a primary or secondary diagnosis of urinary tract infection broken down by financial year, rather than by calendar year.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/05/2019 14:28:15 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4523 label Biography information for Catherine West

1126623

	registered interest
	date	14/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Baby Care Units: Mental Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the adequacy of long-term mental health support given to parents of babies discharged from neonatal units.
	tabling member constituency	Lewisham, Deptford
	tabling member printed	Vicky Foxcroft
	uin	254232
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>Perinatal mental health services are available to all parents, including parents of babies that have been discharged from neonatal units, when they need it.</p><p>In April 2019, NHS England confirmed that new and expectant mothers across the country are now able to access specialist mental health care in the area where they live. The rollout of specialist community services across the whole of England, means that those suffering from perinatal mental health problems are able to access high quality care much closer to home.</p><p> </p><p>The Five Year Forward View for Mental Health committed to invest £365 million from 2015/16 to 2020/21 in perinatal mental health services to ensure that, by 2020/21, at least 30,000 more women each year are able to access evidence-based specialist mental health care during the perinatal period.</p><p> </p><p>The NHS Long Term Plan includes a commitment for a further 24,000 women to be able to access specialist perinatal mental health care by 2023/24. Specialist care will also be available from preconception to 24 months after birth, which will provide an extra year of support. Support will also be extended to fathers and partners of women accessing specialist perinatal mental health services and maternity outreach clinics.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 22/05/2019 16:41:06 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4491 label Biography information for Vicky Foxcroft

1127289

	registered interest
	date	16/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs: Prices
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the affordability of medicines as a result of the redrafted WHO resolution entitled, Improving the transparency of markets for medicines, vaccines and other health-related technologies proposed by Italy on 29 April 2019.
	tabling member constituency	Liverpool, Walton
	tabling member printed	Dan Carden
	uin	255695
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>The United Kingdom has a long-established and globally-recognised track record of assessing the price of new, innovative medicines by their clinical benefit and value, rather than by their development costs or international reference prices.</p><p>The UK will engage constructively with the talks at the World Health Assembly to achieve the best outcome for people here and globally, including in low and middle income countries. Pricing arrangements are the responsibility of Member States and are highly context specific, but the Department supports information sharing and mutual learning initiatives, where appropriate, in seeking to improve value for money for country procurement budgets.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/05/2019 14:32:11 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4651 label Biography information for Dan Carden

1127334

	registered interest
	date	17/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Isotretinoin: Side Effects
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential health risks and psychiatric side-effects of the drug Roaccutane.
	tabling member constituency	Newcastle-under-Lyme
	tabling member printed	Paul Farrelly
	uin	255661
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>As with all medicines in the United Kingdom, the Medicines and Healthcare products Regulatory Agency continuously monitors the safety of isotretinoin-containing medicines. This includes reports of suspected adverse drug reactions submitted by healthcare professionals, patients and carers through the Yellow Card scheme, as well as published and unpublished data. As new evidence on safety emerges it is carefully evaluated and, where appropriate, product information is updated and advice for prescribers and patients is issued.</p><p>Specific assessments of possible psychiatric side effects associated with isotretinoin were considered by an Expert Working Group of the Commission on Human Medicines in 2005 and 2014. In addition, the risk of neuropsychiatric disorders was evaluated in a European review which was completed in 2018. This review concluded that the warnings in the product information for medicines containing isotretinoin regarding possible psychiatric adverse effects reflected what was known.</p><p>Since 1998, warnings regarding the possible risk of developing depression and other psychiatric side effects have been included in the product information for Roaccutane and the generic versions of isotretinoin (the Summary of Product Characteristics for healthcare professionals and the patient information leaflet). The product information for isotretinoin warns that treatment may be associated with possible psychiatric side effects, that particular care needs to be taken in patients with a history of depression; and that all patients on isotretinoin should be monitored for signs of depression and referred for appropriate treatment if necessary. It also states that stopping isotretinoin may not lead to improvement and therefore further psychiatric or psychological evaluation may be necessary.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 22/05/2019 16:42:43 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	1436 label Biography information for Paul Farrelly

1127327

	registered interest
	date	17/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diffuse Intrinsic Pontine Glioma
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of access to NHS support for sufferers of diffuse intrinsic pontine glioma.
	tabling member constituency	Sheffield, Brightside and Hillsborough
	tabling member printed	Gill Furniss
	uin	255692
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>No specific assessment has been made by the Department at this time.</p><p>Care for children with Diffuse Intrinsic Pontine Glioma (DIPG) is co-ordinated and provided by Children’s Cancer Principal Treatment Centres (PTCs) working in conjunction with Paediatric Oncology Shared Care Units. Children’s Cancer PTCs are responsible for planning and delivering treatment for children with DIPG as well as ensuring these children can access wider support services such as psychology services, specialist play services and other therapies.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/05/2019 14:25:19 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4571 label Biography information for Gill Furniss